EHA 2025 Updates-in-Hematology session: Improving outcomes with innovative therapy in β-thalassemia: clinical care discussions

This session was organised and funded by Bristol Myers Squibb.

The session was a scientific presentation and discussion for the purpose of scientific exchange. Neither the session nor the information presented or discussed are for the promotional purpose of influencing prescribing or treatment decisions. The presenters can express their own opinions that may differ from the standpoint of Bristol Myers Squibb. Prescribing decisions are made by healthcare professionals. Always refer to the approved product labeling before prescribing (e.g. SmPC, US Prescribing Information).

At the European Hematology Association (EHA) 2025 Annual Meeting in Milan, Italy, thalassemia expert Maria Domenica Cappellini led an engaging case-based discussion with Sujit Sheth, Abdullah Al Zayed, and Maria Dimopoulou on improving outcomes in patients with β-thalassemia by utilising currently available innovative therapies. They explore available evidence in TD (transfusion-dependent), neoTD, and NTD (non-transfusion-dependent) β-thalassemia and highlight the importance of individualising treatment goals through clinical cases and dynamic panel discussions.

Topics covered:

• β-thalassemia: From pathophysiology to patient care: Sujit Sheth provides background information on the disease state, current unmet needs and treatment landscape
• Innovative therapy in TD β‑thalassemia: Abdullah Al-Zayed leads the audience through two patient cases to illustrate the use of innovative therapy in TD β‑thalassemia followed by a panel discussion moderated by Maria Domenica Cappellini
• Innovative therapy in neoTD and NTD β‑thalassemia: Maria Dimopoulou explores the use of innovative therapies in patients with neoTD and NTD β-thalassemia in two patient cases followed by a panel discussion moderated by Maria Domenica Cappellini

1. University of Milan, Ca’ Granda Foundation IRCCS Maggiore Policlinico Hospital, Milan, Italy
2. Weill Cornell Medicine, New York, USA
3. Qatif Central Hospital, Saudi Arabia
4. Center of Expertise in Hemoglobinopathies, Thalassemia Unit, Laikon General Hospital of Athens, Greece